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Objectives: Polymerase chain reaction (PCR) techniques could provide an ear-
lier diagnosis than traditional techniques (TT) to identify chronic infections in 
patients with musculoskeletal implants. The aim was to determine costs associ-
ated to microorganism’s diagnosis in sonicate samples of musculoskeletal implants, 
comparing the addition of a PCR technique (UnyveroTM i60-ITI) to TT versus TT 
only. MethOds: A preliminary cost analysis was developed to estimate the hos-
pital costs in patients admitted at Fundación Jimenez Diaz Hospital (May-2014 to 
April-2015) for musculoskeletal implant removal due to chronic infection suspect. 
Sonicated samples were tested for microbiological diagnosis using TT. Additionally, 
samples were tested using UnyveroTM i60-ITI. Medical hospitals records were 
reviewed for data collection: sociodemographic data; type, dosing and antibiotic 
treatments; and hospital length of stay (LOS). Intravenous vancomycin and cef-
tazidime were selected as the initial empiric treatment. Replacement to a specific 
antibiotic was performed after microbiological diagnosis. Total estimated costs (€ , 
2015) included antibiotic treatment, hospital stay (€ 1,006 per day) and UnyveroTM 
i60-ITI kits (€ 350 per kit) costs. Results: Ten patients were retrieved for prelimi-
nary analysis (average age: 75.39±6.31 years; 20% men). Hip (40%) and knee (40%) 
were the most frequent implant sites. Average period from implant removal to final 
diagnosis lasted 4.60±1.35 days with TT. UnyveroTM i60-ITI diagnosis was available 
24h after removal. LOS was 24.4 days for TT and 23.3 days for UnyveroTM i60-ITI 
added to TT. The average antibiotic treatment cost was € 1,016.01 for TT and € 976.84 
for UnyveroTM i60-ITI added to TT. Hospital stay cost was € 25,591.26 for TT and 
€ 24,361.98 for UnyveroTM i60-ITI added to TT. The use of UnyveroTM i60-ITI reduced 
average total costs in € 840.67. cOnclusiOns: UnyveroTM i60-ITI PCR for microbio-
logical identification in musculoskeletal implants sonicated is associated to faster 
diagnosis and shorter hospital stays than traditional techniques only, allowing cost 
savings at hospital level.
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Objectives: To perform economic evaluation of donor breast milk (DBM) (using 
clinical breast pump) or artificial formula (AF) for premature infants in the neonatal 
intensive care unit (NICU) for Russian healthcare setting. MethOds: We calculated 
the cost of providing 100 ml of DBM using clinical breast pump and 100 ml of AF for 
premature infants in the NICU. The total cost of providing DBM was measured as: 
the breast pump cost, the individual pumping set cost and staff costs. The cost of 
providing AF was calculated using the mean cost per 100 ml for powdered AF and 
staff costs. We also calculated the cost per averted case of necrotizing enterocolitis 
(NE) for premature infant when breastfeeding instead of the AF is used. The cost 
of the averted NE was obtained using the difference in cost of feeding during the 
period, required for NE development and number of patients “needed to treat” (NNT) 
to prevent 1 NE case derived from the clinical trials. Besides we calculated the DBM 
cost when breast milk fortifier (BMF) is added for low-weight infants. Results: The 
costs per 100 ml of AF and DBM were similar (0,67 EUR and 0,77 EUR respectively). 
The cost per averted case of NE was 344,5 EUR within 35 days that is less than NE 
treatment. The difference in costs (in favor of AF) amounted to 2,87 EUR per 100 ml 
with the use of BMF. cOnclusiOns: The cost of DBM is comparable to the cost of 
AF, with a significant DBM clinical benefit. The costs per averted NE within 35 days 
shows that DBM is acceptable from the position of Russian health care system. 
When calculating the costs of DBM with the use of BMF, DBM costs exceed those 
for AF for more than 5 times.
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Objectives: The material cost for reusing intermittent urinary catheters is lower 
than to use single-use catheters. These cost savings are misleading since com-
plications may increase and lower compliance to the therapy can be expected, 
necessitating use of the second choice therapy form with even more complica-
tions, i.e. an indwelling catheter. The purpose of this cost-comparison study was 
to compare single-use of coated catheters to re-use of non-coated catheters in a 
group of individuals performing intermittent catheterization where some of them 
fail their first choice therapy and switch to an indwelling catheter. MethOds: A 
1-year Markov simulation model with monthly cycles was developed for users of 
daily intermittent catheterization. Individuals who used 4 catheters/day (single-use) 
were compared to individuals who re-used their catheters (1 catheter/day). After 
one month’s use, 18% of the patients in the single-use group were assumed to fail 
their treatment and switch to indwelling catheter. The corresponding frequency in 
the re-use group was 35%. The model was populated with risks from the literature 
for complications (e.g. symptomatic UTI, UTI resistant to antibiotics, pyelonephritis, 
bacteremia, epididymitis, strictures, bladder stones) as well as catheter and health-
care costs for single-use, re-use and indwelling catheters, respectively. Results: 
The total annual catheter cost per patient was 2188 euros (including 163 euros for 
indwelling catheters) in the single-use group and 817 euros (including 317 euros 
for indwelling catheters) in the re-use group. The total annual cost per patient for 
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Objectives: To assess clinical effectiveness, cost-effectiveness, and budget impact 
of Baroreflex Activation Therpay (BAT) in comparison with optimal medical treat-
ment from a hospital and societal perspective in Spain. MethOds: Clinical effec-
tiveness analysis was based on studies collected from medical databases and grey 
literature. Cost effectiveness and budget impact analysis was based on a Markov 
model using epidemiological data, risk functions and clinical management in 
Spain. Results: In a simulated cohort of 55-year-old non-smoker Spanish patients 
with resistant hypertension, BAT significantly reduced the number of heart attacks, 
heart failures, strokes, end-of-stage renal disease and liver transplantations. BAT 
produced 0.78 additional quality-adjusted life years with an incremental societal 
cost of 50.400€ . The resulting incremental cost-effectiveness ratio (65.000€ per 
QALY) was substantially larger than the one estimated for the Northern European 
population (7.800€ per QALY). Qualitative results were robust to all-parameter vari-
ations. cOnclusiOns: Local health characteristics –both, epidemiological data and 
clinical management– have a large weight on cost-effectiveness results.
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Objectives: The objective of this study was to compare the one-year costs 
related to cardiac adverse events post-index procedure discharge of Absorb and 
Xience. MethOds: Using resource use data from ABSORB II, which comprised of 
501 patients randomized 2:1, one-year cardiac-related adverse event costs were 
calculated for the Absorb and Xience groups in 5 countries (France, Germany, 
Italy, The Netherlands, and Spain). Unit costs from the perspective of the health 
system were taken from publicly available data sources (2014 level). Costs were 
calculated by lipid control and diabetic status, both at baseline. Resource use 
categories included hospital admissions, outpatient visits, and cardiac diagnostic 
tests. Results: Mean country costs ranged between 1,140-1,880 Euros for Absorb 
and between 1,310-2,420 Euros for Xience. Mean country-specific per patient cost 
differences (Absorb minus Xience) were 170 Euros in France, 220 Euros in The 
Netherlands, 250 Euros in Germany, 420 Euros in Italy, and 540 Euros in Spain. 
Cost-savings were mainly attributable to the 1.5 unit reduction in mean num-
ber of subsequent percutaneous coronary interventions (PCIs) performed in the 
Absorb arm compared to the Xience group (32 versus 47 per 1,000 population for 
all country data combined). Regardless of lipid status (lipids < 2.0 mmol/l or lipids 
> 2.0 mmol/l) and diabetic status at baseline, cardiac-related adverse event costs 
were reduced with Absorb. Patients with a lipid profile > 2.0 mmol/l at baseline 
had mean country costs that ranged between 1,240-1,930 Euros for Absorb and 
between 1,380-2,540 Euros for Xience. Patients with diabetes at baseline had mean 
country costs that ranged between 1,250-1,920 Euros for Absorb and between 
1,380-3,190 Euros for Xience. cOnclusiOns: These findings suggest potential 
short term cost-savings with Absorb compared to Xience as a result of the reduced 
mean number of repeat PCIs. Future research is necessary to study total direct and 
indirect cost and long-term costs of each intervention.
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Objectives: ISO 15197:2003, states that 95% of the glucose results shall fall within 
±15 mg/dl for concentrations ≤ 75 mg/dl and within ±20% for > 75 mg/dl. Some 
measures which may fall into the recommended thresholds would be out of the 
limits of good metabolic control, not permitting to adjust the therapy, increas-
ing the complication risk, and raising the associated costs. The objective was 
to estimate the annual cost saving in Spain by using glucose meters with better 
accuracy. MethOds: Two samples of true and read values were created accord-
ing to type 1 and 2 diabetes (T1D, T2D) Spanish population data. Proportion of 
readings into the recommended thresholds whose true values were out of the 
limits was calculated. The complication risk associated with those false readings 
was estimated from the clinical trials, and the cost to manage complications was 
calculated from public costs. Cost of strips was included to estimate the total cost. 
The annual cost saving was the difference between the total cost (2015 € ) of all 
Spanish patients in the base case (accuracy level, A20%) and other scenarios (A15%, 
A10%, and A5%). Results: 100% of T1D (n: 116,160) and 32.2% of T2D patients (n: 
957,511) will often need glycaemic self-monitoring, with a cost around 168 mill€ . 
Not detected hyper/hypoglycemia values were estimated: 119,302; 81,025, 55,915 
and 27,332 in A20%, A15%, A10%, and A5%, respectively. Total cost was 193.94 mill€ ; 
183.94 mill€ , 178.29 mill€ , and 172.98 mill€ , respectively, leading a saving cost of 
10.006 mill€ , 15.657 mill€ and 20.960 mill€ , by changing from A20% to A15%, A10% 
and A5% scenario. cOnclusiOns: Blood glucose meters with better accuracy 
leads to decrease complications risk which is associated with cost savings: when 
meters accuracy increases from 20% to 15% and 10%, cost savings are 5.9%, 9.3%, 
and 12.4% on total strips cost.
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disease data. In the absence of comparative clinical evidence, Duodopa and 
Apomorphine were assumed to have equivalent efficacy to DBS. The cost analysis 
covered: device acquisition, implantation, adverse event management, concomitant 
drug use, device replacements and follow-up. Cost data were taken from Swedish 
tariffs, drug list prices and device prices. Costs and QALYs were both discounted 
at 3% per year. Results: The incremental cost-effectiveness ratio for DBS versus 
BMT was SEK 387,313 per QALY gained, using a time horizon of 15 years. DBS was 
predicted to be cost-saving versus Duodopa at 5 years (with a saving of SEK 534,000 
per patient) and at 10 years versus Apomorphine. The key parameters in the model 
were the costs of the DBS device components and the unit costs of the advanced 
drug therapies. cOnclusiOns: The results suggest that DBS is a cost-effective 
intervention compared with BMT, based on the informal threshold used in Sweden 
(SEK 500,000 per QALY gained). When compared against Apomorphine and Duodopa, 
the high initial costs of DBS equipment and implantation are offset in the long-term 
by reduced medication costs.
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Objectives: It is estimated that that approximately 10-30% of all women worldwide 
are affected by menorrhagia once in their life time. Several endometrial ablation 
techniques can be chosen in order to preserve the uterus while stopping or reduc-
ing uterine bleeding. Evidence reports that radiofrequency ablation (RFA) is easier 
and faster to apply and hence result in cost savings compared to other ablation 
devices. MethOds: A sex- and age adjusted database of > 4 million insured were 
analysed (≈5% of the German SHI population). 32,246 patients suffering from men-
orrhagia were identified. These cases were further investigated for the application 
of RFA (intervention group) or other endometrial ablation techniques (rollerball/ 
loop resection/ balloon thermal ablation (control group)). Propensity score matching 
(PSM) was used to make both study groups appropriately comparable. Patients were 
observed for a follow-up period of 2 years. Results: After performing PSM, 50 cases 
were included in the intervention group, while 38 cases were included in the control 
group. Data showed that patients treated with RFA would cause higher costs at the 
time point of treatment compared to others (€ 2,068 vs. € 1,490; n.s.). However, during 
the 2-year follow-up period, the overall costs for controls were € 1,254 higher than 
that for cases (€ 4,561 vs. € 5,815; n.s.). The main cost drivers were medication costs 
from the outpatient setting (€ 495 vs. € 1,228; n.s.), outpatient physician consultations 
(€ 1,355 vs. € 1,683; n.s.) and inpatient treatments (€ 2,025 vs. € 2,726; n.s.). The sav-
ings during follow-up compensated the higher costs in the beginning, so that each 
patient treated with RFA caused € 676 less costs than patients treated with other 
endometrial ablation techniques. cOnclusiOns: Although having small sample 
sizes, the results showed that patients treated with RFA cause less overall costs 
within 2 years. Main reasons for differences in costs were medications prescribed in 
the outpatient setting, inpatient treatments and outpatient physician consultations.
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Objectives: Non-invasive prenatal testing (NIPT) is a method that is based on small 
portions of cell-free fetal DNA (cffDNA) that is present in the woman’s blood during 
pregnancy. Analysis of cffDNA in a blood sample can be used for different types of 
prenatal diagnosis. The use of NIPT to detect trisomies has developed rapidly over 
the past four years. The aim of this study was to examine the costs and cost effec-
tiveness of NIPT to detect trisomy 21 (T21, Down’s syndrome) in Sweden. MethOds: 
The procedures of a cost-analysis and a cost-effectiveness analysis were followed 
using true number of detected T21 as outcome. The main comparator was the 1st 
trimester combined test (nuchal translucency (NT) in combination with levels of 
free-β -hCG and PAPP-A). For the estimation of sensitivity and specificity of T21 
using NIPT, a meta-analysis using data from 32 studies were used. Calculations 
were performed for 10 000 pregnancies with an average age of the women at 30 
years, tested in week 12, and with an average risk of having trisomy 21 (1:526). The 
price of NIPT was set to € 542 (no price is yet available in Sweden). Costs and qual-
ity of life related to living with T21 were not included. Results: Using NIPT as a 
first line procedure increases the costs from about € 2 M to more than € 5 M and its 
cost-effectiveness ratio become about € 2 M per extra true detected T21 compared to 
the combined test. Using NIPT as a second line procedure (following the combined 
test with a cut-off risk at 1:200) leads to reduced costs and fewer procedure-related 
miscarriages, but with 0.04 fewer T21 detected. cOnclusiOns: The use of NIPT to 
test for T21 increases the number of detected T21. It is not possible to clarify what 
testing strategy (if any) that would be considered cost-effective.
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Objectives: Procalcitonin (PCT) is a specific marker for differentiating bacterial 
from non-infective causes of inflammation that was recently proven cost-effective 
complications was 1243 euros in the single-use group and 2067 euros in the re-use 
group. cOnclusiOns: Almost two thirds of the additional catheter cost associated 
with the single-use strategy in comparison to re-using catheters was offset from 
savings due to fewer complications. The decrease in patient suffering from fewer 
complications would also add to the benefits of single-use strategy.
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Objectives: Many patients with overactive bladder (OAB) treated with anticho-
linergic medications (AM) continue to experience urinary symptoms; some may 
be candidates for specialized treatment including sacral neuromodulation (SNM). 
This analysis determined AM costs in OAB patients who were enrolled in the InSite 
study. MethOds: Subjects who failed > 1 AM and were candidates for SNM were 
enrolled in a prospective, multicenter trial. For patients receiving SNM, AM use was 
not permitted during the first 6 months. Thereafter patients could use medication 
if needed. Patient-reported AM cost at 12 months post-implant, based on an eco-
nomic impact questionnaire inquiring about AM cost over the past 2 months, was 
compared to baseline. AM cost at baseline and 6 months for a separate cohort ran-
domized to standard medical therapy (SMT) is included for comparison. Results: 
Of 231 SNM patients, 207 had baseline and follow-up data, of which, 74 (35.7%) 
reported baseline AM costs > $0. Of 74, 4 (5.4%) reported AM costs at 12 months. Of 
133 patients with $0 baseline cost, five (3.8%) reported AM cost > $0 at 12 months. 
Of the 207, the average cost/patient over a 2-month period was $178 at baseline and 
$14 at 12 months post-implant. Of 75 SMT patients, 68 had baseline and follow-up 
data, of which, 28 (41.2%) reported baseline AM costs > $0. Of 28, 19 (67.9%) reported 
AM costs at 6 months. Of 40 patients with $0 baseline cost, 11 (27.5%) reported AM 
cost > $0 at 6 months. Of the 68, the average cost/patient over a 2-month period was 
$176 at baseline and $218 at 6 months. cOnclusiOns: For patients receiving SNM, 
the average AM cost/patient markedly decreased by 92.1% at 12 months. Reductions 
were not seen for patients receiving SMT, where the average AM cost per patient 
increased by 23.9% at 6 months.
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Objectives: Clinical use of next-generation sequencing(NGS) techniques has tre-
mendously risen. This is the result of technological advancements and simultane-
ously decreasing sequencing costs. Although the long-awaited $1,000 genome seems 
near, a clear and complete overview of the costs of NGS techniques is currently 
missing. Moreover, it is still unclear how NGS technologies should be used in clini-
cal practice. This study assesses the costs associated with three NGS technologies: 
Targeted gene panels(TGP), whole exome sequencing(WES), and whole genome 
sequencing(WGS). Additionally, a framework is constructed, balancing costs and 
diagnostic yield. MethOds: The total costs of TGP, WES and WGS were calculated 
at the Radboud university medical center. TGP, WES and WGS can be used in various 
diagnostic workflows in which one test could serve as a pre-test to another. A deci-
sion framework was constructed that takes into account the costs and diagnostic 
yields of various workflows, informing on which workflow is most favourable at 
what diagnostic yields. PRELIMINARY. Results: The per-sample costs of TGP (€ 500) 
are two and five times lower than per-sample costs of WES (€ 1,000) and WGS (€ 2,600), 
respectively. Nevertheless, using it as a pre-test for WES or WGS is only cost-saving 
if its’ diagnostic yield exceeds 60 or 20%, respectively. Using WES as a pre-test for 
WGS saves costs when its’ diagnostic yield exceeds 40%. cOnclusiOns: This study 
is the first complete overview of the costs of NGS technologies. Although it is often 
claimed that the $1,000 genome is near, our study shows that taking into account 
all direct medical costs associated with NGS, the costs of WGS are still consider-
ably higher. The per-sample costs of TGP, WES and WGS are dependent on several 
assumptions, such as annual throughput and coverage. To assure transferability 
of our results, we constructed a flexible framework in which these assumptions 
can be adapted.
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Objectives: Deep Brain Stimulation (DBS) for the treatment of advanced 
Parkinson’s Disease (aPD) is a therapy supported with high-level clinical evidence, 
but to date its cost-effectiveness in the Swedish health care system has not been 
fully evaluated. Our objective was to evaluate the cost-effectiveness of DBS in aPD 
compared with best medical therapy (BMT), Duodopa and Apomorphine from the 
perspective of the Swedish payer. MethOds: A Markov model previously used to 
model the cost-effectiveness of DBS in the UK setting was updated and adapted to 
the Swedish setting, using local cost data, resource use estimates, anti-Parkinson 
drug protocols, hospital price lists, Swedish mortality data and expert opinion. 
Efficacy data were taken from an RCT of DBS versus BMT, combined with long-term 
